Jay Olson
Stock Analyst at Oppenheimer
(3.75)
# 738
Out of 4,712 analysts
239
Total ratings
41.18%
Success rate
10.51%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $3.58 | +458.66% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $5.08 | +490.55% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $5.88 | +240.14% | 2 | Dec 4, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $1.86 | +706.45% | 2 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $60 | $12.12 | +395.05% | 8 | Nov 11, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 → $255 | $149.90 | +70.11% | 25 | Oct 31, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $9 → $8 | $5.73 | +39.62% | 8 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Outperform | $81 → $82 | $69.56 | +17.88% | 14 | Oct 30, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $55 → $60 | $45.29 | +32.48% | 8 | Oct 28, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $375 → $350 | $314.04 | +11.45% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $5.42 | +84.50% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $42.68 | +223.34% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 | $0.32 | +1,758.74% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $62 | $15.74 | +293.90% | 12 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.60 | +400.00% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $14.60 | +228.77% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $263.18 | +44.39% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $139.03 | +57.52% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 | $34.03 | -14.78% | 4 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.23 | +875.61% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.91 | +204.57% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.97 | +407.61% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $41.07 | +131.31% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $17.37 | +9.38% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.66 | +839.85% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $36.33 | +106.44% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.77 | +1,072.79% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $22.50 | +255.56% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $2.18 | +1,046.79% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $8.01 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $2.25 | +2,122.22% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $6.00 | +250.00% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $68 | $21.32 | +218.95% | 3 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $5 → $3 | $0.95 | +215.39% | 5 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.36 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.83 | +371.12% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.09 | - | 3 | Jul 11, 2017 |
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $3.58
Upside: +458.66%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.08
Upside: +490.55%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $5.88
Upside: +240.14%
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $1.86
Upside: +706.45%
Intellia Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $12.12
Upside: +395.05%
Biogen
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $149.90
Upside: +70.11%
Sage Therapeutics
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $5.73
Upside: +39.62%
Incyte
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $69.56
Upside: +17.88%
Revolution Medicines
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $45.29
Upside: +32.48%
Madrigal Pharmaceuticals
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $314.04
Upside: +11.45%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $5.42
Upside: +84.50%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $42.68
Upside: +223.34%
Sep 23, 2024
Upgrades: Outperform
Price Target: $6
Current: $0.32
Upside: +1,758.74%
Aug 14, 2024
Maintains: Outperform
Price Target: $66 → $62
Current: $15.74
Upside: +293.90%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.60
Upside: +400.00%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $14.60
Upside: +228.77%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $263.18
Upside: +44.39%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $139.03
Upside: +57.52%
Jul 30, 2024
Maintains: Outperform
Price Target: $29
Current: $34.03
Upside: -14.78%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.23
Upside: +875.61%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $5.91
Upside: +204.57%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $1.97
Upside: +407.61%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $41.07
Upside: +131.31%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $17.37
Upside: +9.38%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $2.66
Upside: +839.85%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $36.33
Upside: +106.44%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.77
Upside: +1,072.79%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $22.50
Upside: +255.56%
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $2.18
Upside: +1,046.79%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $8.01
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $2.25
Upside: +2,122.22%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $6.00
Upside: +250.00%
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $21.32
Upside: +218.95%
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $0.95
Upside: +215.39%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.36
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.83
Upside: +371.12%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.09
Upside: -